C17orf74 Inhibitors
Energy metabolism is a fundamental cellular process, and inhibitors like 2-Deoxy-D-glucose can disrupt this process, which can lead to altered states of protein function, including potentially those of C17orf74. Rapamycin's role in inhibiting the mTOR pathway can also affect the synthesis of proteins, which may include the modulation of C17orf74's expression or stability.
On the other hand, cellular architecture and dynamics are critical for the proper localization and function of proteins. Agents such as Paclitaxel, Blebbistatin, Y-27632, and ML7 interfere with the cytoskeleton and related motor proteins, which may directly or indirectly influence the cellular role of C17orf74, including its trafficking, degradation, or role within specific cellular compartments. Bafilomycin A1's impact on endosomal-lysosomal acidification could affect the degradation route of C17orf74, while signaling pathway modulators like U73122, SB431542, PD98059, Go6983, and LY294002 can alter the intracellular signaling landscape. These modifications can influence the activity of C17orf74, depending on its involvement in these pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A glycolysis inhibitor that can disrupt energy metabolism, potentially altering the functional state of C17orf74. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can affect protein synthesis, possibly impacting C17orf74 expression levels. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
A microtubule stabilizer that can disrupt cell division, potentially affecting C17orf74's role in the cell cycle. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A vacuolar H+-ATPase inhibitor that can disrupt endosomal-lysosomal acidification, potentially influencing C17orf74 trafficking or degradation. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
An inhibitor of myosin II ATPase activity that can disrupt cytoskeletal dynamics, potentially altering C17orf74's cellular distribution or function. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
A TGF-β receptor inhibitor that can affect TGF-β signaling, potentially altering the regulatory environment of C17orf74. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that can disrupt MAPK/ERK signaling, potentially affecting C17orf74's role in signaling or regulatory pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that can disrupt actin cytoskeleton organization, potentially influencing C17orf74's interactions with cytoskeletal elements. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
A myosin light chain kinase inhibitor that can affect cytoskeletal regulation, potentially impacting C17orf74's cellular functions. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A protein kinase C inhibitor that can alter signal transduction, potentially affecting C17orf74's regulatory roles. | ||||||